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Epidemiology of Systemic Lupus 
Erythematosus
Masakazu Washio, Chikako Kiyohara and Akiko Ohta
Abstract
Epidemiology is the study of the frequency and distribution of diseases and 
factors related to the development of diseases. Systemic lupus erythematosus (SLE) 
is a rare, chronic inflammatory autoimmune disease that affects many tissues 
and organs, whose female-to-male incidence ratio is 6:10 for childbearing age. Its 
chronic intractable nature has a significant impact on medical care utilization, 
activities of daily living, and quality of life. However, the etiology of SLE has not yet 
been elucidated in detail, although genetic factors as well as environmental fac-
tors are thought to play a role in its development. In this chapter, we introduce the 
incidence and the prevalence of SLE as well as factors related to the development of 
SLE and discuss how to prevent the development of SLE.
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1. Introduction
Systemic lupus erythematosus (SLE) is a rare, serious, chronic inflammatory autoim-
mune disease that affects many tissues and organs [1, 2]. The Japanese Ministry of Health 
and Welfare designated SLE as an intractable disease because there is no established 
way to cure or prevent it [3, 4]. Under a nationwide registration system for patients with 
intractable diseases, 55,021 SLE patients were eligible for financial aid from the Japanese 
government in 2007 and the prevalence of SLE was estimated to be 44 per 100,000 per-
sons in Japan [5]. Females are 8.2 times more likely to suffer from SLE than males in Japan 
[5]. Serdula and Rhoads [6] reported that the age-adjusted prevalence of SLE was greater 
in Japanese (18.2/100,000 persons) than White People (5.8/100,000 persons) in Hawaii, 
but they could find no reason for the high prevalence of SLE in Japanese ancestry. The 
etiology of SLE has not yet been elucidated in detail, although genetic factors as well as 
environmental factors are thought to play a role in its development [1]. The discrepancies 
of rates (i.e., higher rates in certain ethnic groups) are in part due to genetic factors as 
well as due to environmental factors such as smoking and dietary habits [7].
In this chapter, we would like to show the incidence and prevalence of systemic 
lupus erythematosus (SLE) and the findings from epidemiological studies on the 
risk/preventive factors for SLE.
2. Diagnosis criterion of SLE (case definition)
The established diagnosis criterion of SLE is needed to estimate the frequency 
and distribution of the patients with SLE. However, case definition is one of the 
Lupus
2
important factors, which may influence the results of epidemiological studies. 
Currently, the American College of Rheumatology (ACR) 1982 revised criteria for 
the classification of SLE [8], as modified in 1972 (ACR-97) [9], are widely used for 
the diagnosis of SLE. The diagnosis of SLE requires the presence of four or more 
of the following 11 criteria, which are (1) malar rash, (2) discoid rash, (3) photo-
sensitivity, (4) oral ulcer (usually painless, observed by a physician), (5) arthritis 
(nonerosive arthritis 2 or more peripheral joints), (6) serositis (a. pleuritis or b. 
pericarditis), (7) renal disorder (a. persistent proteinuria either 0.5 g/day or > 3+ 
if quantification not performed or b. cellular cast), (8) neurologic disorder (a. 
seizures or b. psychosis in the absence of offending drugs or metabolic disorders), 
(9) hematologic disorder (a. hemolytic anemia with reticulocytosis or b. leukopenia 
<4000/mm3 or c. lymphopenia <1500 mm3 or d. thrombocytopenia <100,000 mm3 
in the absence of offending drugs), (10) immunologic disorder (a. antibody to native 
DNA in abnormal titer or b. presence of antibody to Sm nuclear antibody or c. posi-
tive finding of antiphospholipid antibody), and (11) positive antinuclear antibody 
test result. Although the presence of four or more ACR-97 criteria is required for SLE 
classification, all other reasonable diagnoses of diseases other than SLE  
(e.g., neurologic disorder due to uremia, acidosis, or electrolyte imbalance) must be 
excluded [7]. Among the 11 ACR criteria, positive antinuclear antibody test result, 
hematologic disorder, immunologic disorder, and arthritis are the four most com-
mon criteria seen in SLE patients at the time of diagnosis [10–13] (Table 1).
When epidemiological studies are conducted based on the rheumatologist defini-
tion, biopsy-proven lupus nephritis patients may be considered to have SLE even 
though they satisfy fewer than four ACR-97 criteria. In these cases, the rates of SLE 
will be greater than the rates based on the ACR-97. Recently, the Systemic Lupus 
International Clinics (SLICC), which is an international group for the clinical research 
of SLE, presented a new criterion for the classification of SLE in 2012 (SLICC-12) 
[14]. They also validated the ACR-97 and the SLICC-12. The SLICC-12 resulted in 
fewer misclassification than the ACR-97 [14]. Compared with the ACR-97, the SLICC-
12 had greater sensitivity but less specificity [14, 15]. The SLICC case definition of 
Voss et al. [10] Uramoto et al. [11] Lim et al. [12] Izmirly et al. [13]
Manifestation Denmark United States United States United States
n = 107 n = 69 n = 267 n = 232
1. Malar rash 52(49) 18(26.1) 55(20.6) 86(37.1)
2. Discoid rash 15(14) 14(20.3) 40(15.0) 32(13.8)
3. Photosensitivity 51(48) 26(37.7) 43(16.01) 74(31.9)
4. Oral ulcer 9(8) 4(5.8) 61(22.8) 81(34.9)
5. Arthritis 62(58) 37(53.6) 167(62.5) 159(68.5)
6. Serositis 47(44) 22(31.9) 91(34.1) 84(36.2)
7. Renal disorder 37(35) 31(44.9) 91(34.1) 81(34.9)
8. Neurologic disorder 14(13) 2(2.9) 24(9.0) 43(18.5)
9. Hematologic disorder 66(62) 55(79.7) 216(80.9) 188(81.0)
10. Immunologic disorder 99(93) 44(63.8) 187(70.0) 170(73.3)
11. Antinuclear antibody 107(100) 46(66.6) 244(90.4) 213(91.8)
Data are expressed as number (%).
Table 1. 
Distribution of clinical manifestation and laboratory findings at the diagnosis of SLE.
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SLE yielded higher incidence and prevalence estimates than the ACR-97 case defini-
tion [15]. Thus, the incidence and prevalence of SLE are influenced by the diagnosis 
criterion of SLE. Therefore, interpretation of incidence and prevalence of SLE also 
take into account differences in the methodology used to determine these rates.
3. Incidence and prevalence of SLE
In the United Kingdom, Rees et al. [16] found that the incidence and prevalence 
of SLE in White People (6.73/100,000 person-years and 134.5/100,000 persons) 
were smaller than those in other ethnic groups such as Black African (13.78/100,000 
person-years and 179.8/100,000 persons), Black Caribbean (31.46/100,000 person-
years and 517.5/100,000 persons), and Indian (9.9/100,000 person-years and 
193.1/100,000 persons) (Table 2). In addition to the United Kingdom, American 
epidemiologists also reported that the incidence and prevalence of SLE in White 
First 
author 
(year)
Country Year Definition of 
SLE
Characteristics 
of study group
Incidence 
(per 
100,000 
person-
years)
Prevalence 
(per 
100, 000 
persons)
Rees 
(2016) [16]
United 
Kingdom
1999–
2012
Clinical Practice 
Research 
Datalink (CPRD)
White People 6.73 134.5
Black African 13.78 179.8
Black Caribbean 31.46 517.5
Indian 9.9 193.1
Serdula 
(1979) [6]
United States 
(Hawaii)
1970–
1975
American 
Rheumatism 
Association 
(ARA)—
preliminary 
criteria
White People NA 5.8
Chinese NA 24.1
Filipino NA 19.9
Hawaiian NA 20.4
Japanese NA 18.2
Lim (2014) 
[12]
United States 
(Georgia)
2002–
2004
ACR-97 criteria White People 2.7 32.7
Black People 8.7 118.5
Somers 
(2014) 
[17]
United States 
(Michigan)
2002–
2004
ACR-97 criteria White People 3.7 47.5
Black People 7.9 111.6
Asian/Pacific 
Islanders
NA 24.9
Dall’Ella 
(2017) 
[18]
United States 
(California)
2007–
2009
ACR-97 criteria White People 2.8 NA
Black People 15.5 NA
Asian/Pacific 
Islanders
4.1 NA
NA, not available.
Table 2. 
Incidence and prevalence of SLE by ethnic group in the United Kingdom/the United States.
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First author 
(year)
Country Year Definition of 
SLE
Characteristics 
of study group
Incidence 
(per 100,000 
person-
years)
Prevalence 
(per 
100, 000 
persons)
Uramoto 
(1999) [11]
United States 
(Minnesota)
1950–
1979
ACR-82 criteria Overall 1.51 NA
Females 2.47 NA
Males 0.50 NA
United States 
(Minnesota)
1980–
1992
ACR-82 criteria Overall 5.56 NA
Females 9.40 NA
Males 1.54 NA
Lim (2014) 
[12]
United States 
(Georgia)
2002–
2004
ACR-97 criteria All population 5.6 73.0
Females 9.2 127.6
Males 1.8 14.7
White People 2.7 32.7
Females 4.7 59.0
Males 0.7 7.5
Black People 8.7 118.5
Females 13.4 196.2
Males 3.2 23.7
Somers 
(2014) [17]
United States 
(Michigan)
2002–
2004
ACR-97 criteria All population 5.5 72.8
Female 
population
9.3 128.7
Male population 1.5 12.8
Dall’Ella 
(2017) [18]
United States 
(California)
2007–
2009
ACR-97 criteria All population 4.6 NA
Females 8.6 NA
Males 0.7 NA
White People 2.8 NA
Females 5.3 NA
Males 0.6 NA
Black People 15.5 NA
Females 30.5 NA
Males 2.1 NA
Asian /Pacific 
Americans
4.1 NA
Females 7.2 NA
Males 0.6 NA
Izmirly 
(2017) [13]
United States 
(New York)
2007–
2009
ACR-97 criteria Overall 4.6 62.2
Females 7.9 107.4
Males 1.0 12.5
United States 
(New York)
2007–
2009
SLICC Overall 6.2 73.8
Females 10.3 128.3
Males 1.7 13.8
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First author 
(year)
Country Year Definition of 
SLE
Characteristics 
of study group
Incidence 
(per 100,000 
person-
years)
Prevalence 
(per 
100, 000 
persons)
Barnabe 
(2012) [19]
Canada 1994–
2007
Diagnosed 
in clinical 
setting (ICD-9, 
ICD-10)
Females NA 27.3
Males NA 3.2
First Nations 
females
NA 32.2
First Nations 
males
NA 3.2
non-First 
Nations females
NA 27.1
non-First 
Nations males
NA 3.2
Somers 
(2007) [20]
United 
Kingdom
1990–
1999
Clinical Practice 
Research 
Datalink 
(CPRD)
All population 4.87 NA
Females 8.01 NA
Males 1.60 NA
Rees (2016) 
[16]
United 
Kingdom
1999–
2012
Clinical Practice 
Research 
Datalink 
(CPRD)
All population 4.91 64.6–97.0
Female 
population
8.34 NA
Male population 1.44 NA
Arnaud 
(2014) [21]
France 2010 Diagnosed in 
clinical setting 
(ICD10)
All population 3.32 47.0
Females 5.51 79.1
Males 0.92 11.8
Zou (2014) 
[22]
China 2009–
2010
Diagnosed by 
rheumatologists 
(ACR-97 
criteria)
All population NA 37.6
Females NA 70.3
Males NA 6.4
Yu (2013) 
[23]
Taiwan 2000–
2008
Diagnosed in 
clinical setting 
(ICD9)
All population 8.4 37.0
Females 15.0 66.6
Males 1.9 8.5
Shim (2014) 
[24]
South Korea 2009 Diagnosed 
(ACR-criteria) 
(ICD10)
All population 2.8 24.9
Females 5.1 42.9
Males 0.6 7.0
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People were smaller than those in other ethnic groups in the United States  
[6, 12, 17, 18] (Table 2). The disease burden of SLE is highest in Black People  
[17, 18], followed by Asian/Pacific islanders [17] and White People in the United 
States [17, 18], which may be related to genetic and environmental factors.
As shown in Table 3, the incidence and prevalence of SLE are greater in 
females than in males in all studies regardless of ethnic group or countries 
[11–13, 16–27]. Age-adjusted incidence of SLE in females was 8.8–14.5 times 
greater than in males in California, the United States (i.e., 12.3-fold female 
excess in all population, 8.8-fold female excess in White People, 14.5-fold 
female excess in Black People, and 12.0-fold female excess in Asian/Pacific 
islanders) [18], while the age-adjusted incidence of SLE in females was 7.8–14.8 
times greater than that in males in East Asia (i.e., 7.8-fold female excess in 
Taiwan [23], 8.5-fold female excess in South Korea [24], and 14.8-fold female 
excess in Japan [27]).
SLE is more common in women than men across all age groups, and this female 
predominance is especially noteworthy in the 15- to 64-year age group, wherein the 
male-to-female ratios of age-group incidence show a 6- to 10-fold female excess 
[28], which suggests that female sex hormones may play an important role in the 
development of SLE [28]. The Nurses’ Health Study [29] revealed that oral concep-
tive use increased the risk of SLE in the United States, whereas Bernier et al. [30] 
reported that it was not past use but current use of oral contraceptive pills that 
increased the risk of SLE in the United Kingdom. These studies [29, 30] also suggest 
that female sex hormones such as estrogen may play an important role in the devel-
opment of SLE. In addition to sex hormones, both X-linked and autosomal immune 
genes are also regulated epigenetically and likely contribute to the sex difference in 
the incidence of SLE [31].
First author 
(year)
Country Year Definition of 
SLE
Characteristics 
of study group
Incidence 
(per 100,000 
person-
years)
Prevalence 
(per 
100, 000 
persons)
Yamamoto 
(1986) [25]
Japan 1972–
1983
Diagnosed by a 
rheumatologist 
(ACR criteria)
All population 2.0 NA
Females 3.7 NA
Males 0.25 NA
Ohno 
(1992) [26]
Japan 1992 Diagnosed in 
clinical setting 
(ACR-82 
criteria)
All population NA 29.1
Females NA 52.3
Males NA 5.0
Iseki (1994) 
[27]
Japan 1972–
1991
ACR-82 criteria All population 3.0 NA
1972–
1991
Females 1.6–4.7 6.6–68.4
1973–
1991
Males 0.4–0.8 0.8–7.0
NA, not available.
Table 3. 
Incidence and prevalence of SLE in females and males in selected countries.
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4. Factors related to the development of SLE
Although genetic factors are suggested to play an important role in the develop-
ment of SLE, nongenetic factors are also suggested to play a role in the development 
of SLE [1, 7]. In addition to genetic susceptibility, hormonal and reproductive expo-
sures (e.g., endogenous estrogens, estrogen replacement therapy), occupational and 
environmental exposures (e.g., silica, ultraviolet light), and infectious exposures 
(e.g., Epstein-Barr virus) are suggested to influence the risk of SLE [1, 7]. Complex 
interactions between genetic and environmental factors are thought to play a role in 
the development and progression of SLE [7].
4.1 Sex hormones and reproductive issues in females
The incidence of SLE is greater in females than in males in all studies regardless 
of ethnic group or countries [11–13, 16–27]. Although SLE occurs predominantly 
in females, the incidence of SLE is low before puberty and after menopause (i.e., 
outside the reproductive ages) [32]. Sex difference in susceptibility is largest during 
the reproductive ages [33], which suggests that high endogenous estrogen concen-
trations may increase the risk for the development of SLE. Estrogens enhance B 
cell activation (e.g., immunoglobulin production including anti-ds-DNA), while 
they suppress T cell activity (e.g., proliferative response to mitogens and antigens, 
interleukin 2 production) [32].
Costenbader et al. [29] reported that menarche at a younger age (10 years old 
or younger vs. 12 years old: RR 2.1, 95% CI = 1.4–3.2) increased the risk for the 
development of SLE in the NHS 1976–2002 and the NHSII 1989–2003. In addition, 
they also reported that age at menarche was inversely associated with a risk for the 
development of SLE (vs. 12 years old: RR = 2.1 for 10 years or younger, RR = 1.2 for 
11 years old, RR = 1.0 for 12 years old, 1.1 for 13 years old, and RR = 1.1 for 14 years 
old, and RR = 1.0 for 14 years old or older, p for trend = 0.02) [29]. These findings 
suggest that the exposure to high concentrations of endogenous estrogen at early 
age may increase the risk for the development of SLE.
On the other hand, Bernier et al. [30] reported that current use of combined 
oral contraceptives increased the risk of SLE (RR 1.54, 95% CI = 1.15–2.07), but 
past use of combined oral contraceptives did not increase the risk (RR 1.06, 95% 
CI = 0.85–1.33). In addition, they also reported that the risk of SLE increased with 
the dose of ethinyl estradiol (vs. nonusers: RR 1.42 for 30 μg or less, RR 1.63 for 
31–49 μg, and RR 2.92 for 50 μg), while Costenbader et al. [29] reported that use 
of oral conceptive (vs. never: RR 1.5, 95% CI = 1.1–2.1) and use of postmenopausal 
hormones (vs. never: RR 1.9, 95 % CI = 1.2–3.1) increased the risk for development 
of SLE in the Nurses’ Health Study. These findings suggest that use of exogenous 
estrogens may increase the risk for the development of SLE.
Costenbader et al. [29] also reported that postmenopausal women primary after 
surgical menopause (vs. premenopausal: RR 2.3, 95% CI = 1.2–4.5) and early age 
of menopause (younger than 47 years old vs. 53 years old and older: RR 2.2, 95% 
CI = 0.9–5.4) showed an increased risk for the development of SLE. In their study, 
most of females who developed SLE after menopause were those with surgical 
menopause (i.e., bilateral oophorectomy) and were more likely to have taken 
postmenopausal hormones [29]. The increased risk of developing SLE among post-
menopausal females in their study may be partly explained by the use of postmeno-
pausal hormones (RR 1.9, 95% CI = 1.2–3.1) [29] and the surgery (vs. no surgery: 
surgery without blood transfusion: OR 1.54, 95% CI = 1.05–2.26; surgery with blood 
transfusion: OR 4.46, 95% CI = 1.99–10.00) [34].
Lupus
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Ulff-Møller et al. [35] reported that live birth showed a decreased risk of SLE among 
Danish females (RR 0.74, 95% CI = 0.64–0.86), while Washio et al. [34] reported that 
live birth (OR 0.23, 95% CI = 0.09–0.59) decreased the risk of SLE and found a positive 
association between the risk of SLE and the number of living children delivered among 
Japanese females (vs. 0; OR 0.27 for one to two children, and OR 0.14 for three or more 
children, p for trend <0.01). On the other hand, Cooper et al. [36] could not find any 
meaningful association between the risk of SLE and number of live births. However, 
they found that breast-feeding was associated with a decreased risk of SLE (OR 0.6, 
95% CI = 0.4–0.9) among females in the United States [36]. These findings suggest that 
lactation may play an important role in reducing the risk of SLE among women with 
live-born children because serum estrogen levels are usually at or below the lower range 
for the early follicular phase of the normal menstrual cycle during the lactation [37].
4.2 Tobacco smoking and alcohol drinking
Several researchers suggested that smoking increased the risk of SLE [38–42]. 
Ghaussy et al. [39] reported a significantly increased risk of SLE in both current and 
former smokers compared with never smokers (current smokers: OR 6.69, 95%  
CI = 2.59–17.28, former smokers: OR 3.62, 95% CI = 1.22–10.70) in the United States. 
On the other hand, others reported no association with smoking history (i.e., current, 
former, or never-smoker) and the risk of SLE in the United States [43, 44]. A meta-
analysis by Costenbader et al. [45] revealed an increased risk of SLE among current 
smokers compared with nonsmokers (summary OR 1.50, 95% CI = 1.09–2.08).
The Kyushu Sapporo SLE study (i.e., the KYSS Study) was a hospital-based case-
control study to evaluate nongenetic and genetic risk factors for the development of 
SLE among Japanese females [42]. All SLE patients fulfilled the American College of 
Rheumatology 1982 revised criteria for SLE [8]. In the KYSS study, Kiyohara et al. 
[46] reported that (1) compared with nonsmokers, smokers showed an increased 
risk of SLE (vs. nonsmokers: OR 2.49 for former smokers, and OR 3.06 for current 
smokers, p for trend <0.01). In addition, the risk of SLE increased with number of 
cigarettes smoked/day during peak smoking period (vs. 0/day: OR 2.77 for 1–19/day, 
and OR 3.29 for 20+/day, p for trend<0.01) [46]. Since hydrazine, a drug containing 
aromatic amines, is a known inducer of SLE [47], aromatic amines in cigarette smoke 
may partly explain the association between smoking and the risk of SLE.
Some studies suggested that alcohol consumption may decrease the risk of SLE 
[38, 40, 41]. Hardy et al. [38] reported a dose-response negative association between 
alcohol drinking and SLE risk (vs. 0 unit of alcohol: OR 0.73 for 1–2 units, OR 0.41 
for 3–5 units, OR 0.47 for 6–10 units, and OR 0.30 for more than 10 units, p for 
trend <0.01). On the other hand, other studies failed to show an inverse association 
between alcohol drinking and SLE risk [37, 40]. A meta-analysis by Wang et al. 
[48] demonstrated that moderate alcohol drinking might have a protective effect 
on the development of SLE (vs. none: summary OR 0.73, 95% CI = 0.547–0.954). In 
the KYSS study, Kiyohara et al. [46] found a U-shape relationship between alcohol 
consumption and SLE risk among Japanese females (vs. 0 ml/week: OR 0.52, 95% 
CI = 0.31–0.86 for 1–70 ml/week, OR 0.38, 95% CI = 0.19–0.76 for 71–210 ml/week, 
and OR 0.67, 0.31–1.46 for 211 ml/week or more). These findings suggest that light to 
moderate alcohol consumption may decrease the risk of SLE.
Although there are potential biases associated with retrospective assessment of 
exposures and selection of cases and controls in a case-control study [49], Kiyohara 
et al. [46] reported that ever-smokers with drinking alcohol (OR 3.44, 95%  
CI = 2.03–5.82), nonsmokers without drinking alcohol (OR 2.56, 95% CI = 1.57–4.17), 
and ever-smokers without drinking alcohol (OR 6.98, 95% CI = 2.87–17.0) showed a 
greater risk of SLE than nonsmokers with drinking alcohol in Japanese women.
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4.3 Occupational exposures and chemicals
Crystalline silica exposure is known to increase the risk of SLE [50, 51]. Finckh 
et al. [52] reported that exposure to silica for more than 1 year increased the risk 
of SLE (OR 4.3, 95% CI = 1.7–11.2). They also reported that the risk of SLE was 
associated with the duration of exposure to silica (vs. less than 1 year: OR 4.0 for 
1–5 years, and OR 4.9 for more than 5 years, p for trend = 0.01) [52]. Parks et al. 
[53] reported a positive relationship between a history of silica exposure and SLE 
risk (vs. none: OR 1.6 for low, and OR 3.1 for medium or high, p for trend = 0.003).
On the other hand, Cooper et al. [54] reported that occupational silica exposure 
increased the risk of SLE among never-smokers (vs. no-silica exposure: OR 2.6, 95% 
CI = 1.2–5.7) but not among ever-smokers (vs. no-silica exposure: OR 0.99, 95% 
CI = 0.46–2.1), which suggests that smoking may play a more important role in the 
development of SLE than silica exposure.
Cooper et al. [43] reported that any use of permanent dyes increased the risk of 
SLE (OR 1.5, 95% CI = 1.0–2.2) in the United States. On the other hand, Sanchez-
Guerrero et al. [44] failed to find a positive association between use of permanent 
hair dye and SLE risk (ever-users vs. never-users: OR 0.96, 95% CI = 0.63–1.47) in 
the Unites States.
4.4 Ultraviolet radiation exposure
Washio et al. [42] reported that walking increased the risk of SLE in Kyushu, 
southern Japan with a temperate climate (30 min/day or more vs. less than 
30 min/day: OR 2.07, 95% CI = 1.14–3.76) but failed to increase the risk of SLE in 
Hokkaido, northern Japan with a subarctic climate (30 min/day or more vs. less 
than 30 min/day: OR 1.13, 95% CI = 0.46–2.79). In this study, walking may be a 
surrogate of staying outdoors with exposure to strong sunlight [42]. On the other 
hand, Cooper et al. [54] reported that outdoor work in the 12 months preceding 
diagnosis (OR 2.0, 95% CI = 1.0–3.8) increased the risk of SLE. In their study, a 
larger variation in the association between outdoor work and SLE risk was seen 
when examined within categories of sun reaction to midday sun (vs. none; OR 0.75 
for tan or darken without burning, OR 2.7 for sunburn, and OR 7.9 for sunburn 
with blistering or rash) [54]. However, it is controversial whether ultraviolet (UV) 
radiation exposure itself plays a role in the development of SLE although UV radia-
tion exposure may exacerbate preexisting SLE [50].
4.5 Family history
Family history of SLE [40, 55] as well as family history of connective tissue 
diseases/autoimmune diseases [40, 41, 55] is reported to increase the risk of 
SLE. Alarcón-Segovia et al. [56] reported that there was familial aggregation of SLE 
and of RA in SLE patients. These findings suggest that predisposing genes of auto-
immune diseases as well as environmental risk factors sharing in family members 
may play a role in the development of autoimmune diseases including SLE.
4.6 Genetic susceptibility
It is widely accepted that SLE development requires environmental factors 
acting on a genetically predisposed individual. Studies of twin concordance are 
commonly used in epidemiology to estimate the role of genetics and the influ-
ence of environmental factors on disease susceptibility. Disease concordance is 
much higher in monozygotic twins (24–57%) than in dizygotic twins (2–5%), 
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suggesting that a genetic factor may play a role in the development of SLE [57, 58]. 
The genetic basis of SLE is very complex; it has been estimated that over 100 genes 
may be involved in SLE susceptibility [59], but it is difficult to predict how many 
genes contribute to SLE susceptibility. Exposure to reactive oxygen species (ROS) 
via cigarette smoking is thought to contribute to the development of SLE. ROS 
is considered to promote the autoimmune response [60]. The cytochrome P450 
(CYP)1A1 and glutathione S-transferase (GST) M1 enzymes are critical for the 
functionalization of genotoxic substances in cigarette smoke. The CYP1A1 enzyme 
contributes to the phase I metabolic activation and formation of ROS, whereas 
the GSTM1 enzyme plays a critical role for phase II detoxification of activated 
carcinogens or ROS [61, 62]. Extensive studies have been performed on the pos-
sible associations between polymorphisms of CYP1A1 and GSTM1 and cancer 
susceptibility [63–65]. Similarly, the N-acetyltransferase (NAT) enzyme is involved 
in the metabolism and detoxification of cytotoxic and carcinogenic compounds as 
well as ROS [66]. It has been suggested that N-acetylation of polycyclic aromatic 
hydrocarbons (PAHs) by the NAT2 enzyme may be associated with ROS production 
[67]. ROS increase immunogenicity of DNA, LDL, and IgG, generating ligands for 
which autoantibodies show higher avidity [60]. Tumor necrosis factor r superfamily 
member 1B (TNFRSF1B) is a receptor for TNF-α and is considered to mediate vari-
ous biological effects including generation of ROS and the subsequent intracellular 
proinflammatory signaling events [68]. Furthermore, cigarette smoking has been 
suggested to influence TNFRSF1B production [69, 70]. Representative functional 
polymorphisms of the CYP1A1, GSTM1, NAT2, and TNFRSF1B genes are CYP1A1 
rs464903, GSTM1 deletion, NAT2 genotypes determined by NAT2*4, *5B, *6A, or 
*7B allele and TNFRSF1B rs1061622. Considering that exposure to ROS via cigarette 
smoking may be contributed to the development of SLE, it is important to study the 
association between SLE and the polymorphisms involved in metabolism of tobacco 
smoke and ROS production. We conducted candidate gene association studies 
(hypothesis-driven approach) of SLE in female Japanese subjects with special refer-
ence to the interaction between the polymorphisms involved in ROS production and 
cigarette smoking [71–74]. CYP1A1 rs4646903 (OR of the CC genotype = 2.47, 95% 
CI = 1.28–4.78) [71] and NAT2 genotypes (OR of the intermediate acetylator and 
slow acetylator genotypes combined = 2.34, 95% CI = 1.36–4.02) were significantly 
associated with SLE risk [72]. TNFRSF1B rs1061622 was marginally associated with 
an increased risk of SLE (OR of the G allele possession = 1.56, 95% CI = 0.99–2.47) 
[71]. There were significant additive interactions between smoking and any one 
of the following: CYP1A1 rs4646903, NAT2, or TNFRSF1B rs1061622 [72–74]. 
Replication of findings is very important before any causal inference can be drawn. 
Testing replication in different populations is an important step. Future studies 
involving larger control and case populations, precisely and uniformly defined 
clinical classification of SLE and better exposure histories, will undoubtedly lead to 
a more thorough understanding of the role of the genetic polymorphisms involved 
in ROS production in SLE development.
5. Applications of findings in the epidemiological studies
Descriptive epidemiologic studies of SLE have been conducted not only in the 
Western countries (e.g., the United Kingdom, France, the United States, Canada) 
but also in Asian countries (e.g., China, South Korea, Japan). The prevalence of 
SLE provides useful information for the needs of health services for SLE patients. 
Information of the age- and sex-specific incidence and prevalence of SLE can be 
used to estimate the number of newly diagnosed SLE patients and the total number 
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of SLE patients in a community whose age and sex structure is known. On the other 
hand, the discrepancies of rates between different groups (e.g., different ethnic 
groups in the same country, different countries), which may be partly due to genetic 
factors as well as due to environmental factors [6], may give epidemiologists clues to 
plan epidemiological studies to determine a risk factor for SLE.
Observational studies such as case-control studies and cohort studies have been 
conducted to determine factors related to the development of SLE (i.e., risk factors, 
preventive factors) [49, 75]. After determining risk factors, preventive action will 
be started to control the level of exposure to a risk factor for SLE (i.e., reducing the 
risk of SLE) as well as to undergo a medical examination for the early detection of 
SLE for persons who are at special risk (e.g., silica [50–54]) (i.e., high risk strategy 
[76]). The size of relative risk/odds ratio indicates the strength of association between 
an exposure and a risk of SLE. For a public health perspective, however, the attribut-
able risk of SLE is more important than the relative risk. The attributable risk is the 
difference in the risk of SLE between the exposed and the unexposed persons [49, 75]. 
 The population attributable risk is the incidence of SLE in a population that is asso-
ciated with an exposure to a risk factor, which is useful for determining the relative 
importance of exposures for the entire population [49, 75]. When the proportion of 
exposed persons is large, the population attribute risk is high even if the relative risk 
is small. More cases of SLE may develop in a large number of persons who are at a 
small risk than in the small number who are at high risk.
Smoking is an avoidable risk factor for SLE [38–42, 45] as well as for cancer 
[77] and cardiovascular diseases [78]. Therefore, antismoking education for both 
smokers and nonsmokers throughout lifetime (i.e., population strategy [76]) is 
important to reduce the incidence of SLE as well as the incidence of cancer and 
cardiovascular diseases in the general population.
6. Summary
The incidence and prevalence of SLE vary with sex, age, ethnicity, and the way 
how to detect SLE patients (e.g., case definition). SLE is more common in women 
than men across all age groups, and this female predominance is especially note-
worthy during the reproductive ages [28], which suggests that female sex hormones 
may play an important role in the development of SLE.
A lower incidence and prevalence of SLE has been constantly observed in White 
People than in Black People [12, 17, 18] as well as Asian/Pacific Islanders [6, 17, 18] 
in the United States, while the incidence and prevalence of SLE is lower in White 
People than in Black African, Black Caribbean, and Indian [16]. The discrepancies 
of rates between ethnic groups are in part due to genetic factors as well as due to 
environmental factors such as smoking and dietary habits [7].
There are worldwide differences in the incidence and prevalence of SLE [79]. 
In addition to genetic factors and environmental factors, the way to detect SLE 
patients (e.g., case definition) is an important factor, which influences the incidence 
and prevalence of SLE. Ighe et al. [15] reported that the SLICC case definition 
of SLE yielded higher incidence and prevalence estimates than the ACR-97 case 
definition.
In this chapter, we introduce factors related to the development of SLE as well 
as incidence and prevalence of SLE. Among the reproductive issues, menarche 
at a younger age [29], use of contraceptive [29, 30], and use of postmenopausal 
hormones [29] increase the risk of SLE, while breast-feeding is associated with a 
decreased risk of SLE. Among environmental factors, tobacco smoking increases 
the risk of SLE [38–42, 46], while light to moderate alcohol drinking decreases 
Lupus
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the risk of SLE [46]. On the other hand, the exposure to crystalline silica [50, 51], 
silica [52, 53], strong sunlight [42, 54], and ultraviolet radiation [50] increase the 
risk of SLE. Among genetic factors, CYP1A1 rs4646903 and NAT2 genotypes are 
associated with an increased risk of SLE, while TNFRSF1B rs1061622 is suggested 
to increase the risk of SLE [71–74]. In order to reduce the risk of SLE, we should 
reduce the exposure to avoidable risk factors such as smoking, contraceptives, 
crystalline silica, silica, strong sunlight, or ultraviolet radiation.
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